NASDAQ:IRMD Iradimed (IRMD) Stock Price, News & Analysis → AI “wealth window” is closing June 25th (From Paradigm Press) (Ad) Free IRMD Stock Alerts $43.42 -0.27 (-0.62%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$42.81▼$43.7750-Day Range$40.36▼$45.0052-Week Range$36.12▼$51.04Volume39,540 shsAverage Volume52,091 shsMarket Capitalization$549.87 millionP/E Ratio30.79Dividend Yield1.38%Price Target$62.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Iradimed alerts: Email Address Iradimed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside43.9% Upside$62.50 Price TargetShort InterestHealthy1.31% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainability-0.85Upright™ Environmental ScoreNews Sentiment0.54Based on 11 Articles This WeekInsider TradingN/AProj. Earnings Growth23.74%From $1.39 to $1.72 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.99 out of 5 starsMedical Sector3rd out of 905 stocksSurgical & Medical Instruments Industry1st out of 95 stocks 3.5 Analyst's Opinion Consensus RatingIradimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIradimed has only been the subject of 3 research reports in the past 90 days.Read more about Iradimed's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.31% of the float of Iradimed has been sold short.Short Interest Ratio / Days to CoverIradimed has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Iradimed has recently decreased by 3.23%, indicating that investor sentiment is improving. Previous Next 2.5 Dividend Strength Dividend YieldIradimed pays a meaningful dividend of 1.34%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthIradimed does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Iradimed is 42.55%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Iradimed will have a dividend payout ratio of 34.88% next year. This indicates that Iradimed will be able to sustain or increase its dividend.Read more about Iradimed's dividend. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIradimed has received a 67.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Real-time vital parameter monitors for MRI machines", "Intravenous therapy equipment for MRI machines", and "ECG monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for Iradimed is -0.85. Previous Next 3.1 News and Social Media Coverage News SentimentIradimed has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Iradimed this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for IRMD on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows1 people have added Iradimed to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iradimed insiders have not sold or bought any company stock.Percentage Held by Insiders42.60% of the stock of Iradimed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.34% of the stock of Iradimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Iradimed's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Iradimed are expected to grow by 23.74% in the coming year, from $1.39 to $1.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iradimed is 30.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.10.Price to Earnings Ratio vs. SectorThe P/E ratio of Iradimed is 30.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 190.01.Price to Book Value per Share RatioIradimed has a P/B Ratio of 7.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Iradimed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About Iradimed Stock (NASDAQ:IRMD)IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.Read More IRMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRMD Stock News HeadlinesMay 6, 2024 | finance.yahoo.comIRadimed Corporation (NASDAQ:IRMD) Q1 2024 Earnings Call TranscriptMay 5, 2024 | finance.yahoo.comIRADIMED CORPORATION Just Beat EPS By 6.7%: Here's What Analysts Think Will Happen NextMay 9, 2024 | Paradigm Press (Ad)AI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.May 4, 2024 | finance.yahoo.comIRADIMED First Quarter 2024 Earnings: Beats ExpectationsMay 2, 2024 | finance.yahoo.comiRadimed Corp (IRMD) Reports Record Q1 Revenue, Surpasses Analyst EstimatesMay 2, 2024 | globenewswire.comIRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per ShareMay 1, 2024 | msn.comiRadimed Q1 2024 Earnings PreviewApril 30, 2024 | finance.yahoo.comHere's Why We Think IRADIMED (NASDAQ:IRMD) Is Well Worth WatchingMay 9, 2024 | Paradigm Press (Ad)AI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.April 25, 2024 | globenewswire.comIRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conference Call on May 2ndApril 24, 2024 | benzinga.comiRadimed Stock (NASDAQ:IRMD), Analyst Ratings, Price Targets, PredictionsApril 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alcon (ALC) and Iradimed (IRMD)March 15, 2024 | finance.yahoo.comIRMD Jul 2024 60.000 callMarch 13, 2024 | globenewswire.comIRADIMED CORPORATION To Participate at the 36th Annual Roth ConferenceMarch 13, 2024 | wsj.comiRadimed Corp.February 26, 2024 | finance.yahoo.comCalculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)February 26, 2024 | finance.yahoo.comCalculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)February 19, 2024 | finance.yahoo.comShould You Invest in IRadimed Corporation (IRMD)?February 17, 2024 | finance.yahoo.comIRMD Mar 2024 45.000 putFebruary 17, 2024 | finance.yahoo.comIRMD Mar 2024 40.000 callFebruary 15, 2024 | finance.yahoo.comIRMD Feb 2024 44.520 callFebruary 11, 2024 | finance.yahoo.comInstitutional investors own a significant stake of 39% in IRadimed Corporation (NASDAQ:IRMD)February 9, 2024 | finance.yahoo.comIRadimed Corporation (NASDAQ:IRMD) Q4 2023 Earnings Call TranscriptFebruary 8, 2024 | finance.yahoo.comiRadimed Corp (IRMD) Reports Record Revenues and Robust Earnings Growth in Q4 and Full-Year 2023February 8, 2024 | markets.businessinsider.comIRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial ResultsFebruary 8, 2024 | washingtonpost.comIRadimed: Q4 Earnings SnapshotFebruary 7, 2024 | benzinga.comiRadimed's Earnings OutlookSee More Headlines Receive IRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iradimed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today5/08/2024Ex-Dividend for 5/30 Dividend5/17/2024Dividend Payable5/30/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:IRMD CUSIPN/A CIK1325618 Webwww.iradimed.com Phone(407) 677-8022Fax407-677-5037Employees148Year FoundedN/APrice Target and Rating Average Stock Price Target$62.50 High Stock Price Target$65.00 Low Stock Price Target$60.00 Potential Upside/Downside+43.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.41 Trailing P/E Ratio30.79 Forward P/E Ratio31.24 P/E GrowthN/ANet Income$17.19 million Net Margins26.48% Pretax Margin33.44% Return on Equity24.63% Return on Assets20.54% Debt Debt-to-Equity RatioN/A Current Ratio9.44 Quick Ratio7.77 Sales & Book Value Annual Sales$65.56 million Price / Sales8.38 Cash Flow$1.38 per share Price / Cash Flow31.39 Book Value$5.66 per share Price / Book7.67Miscellaneous Outstanding Shares12,660,000Free Float7,269,000Market Cap$549.70 million OptionableOptionable Beta0.86 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Roger E. Susi (Age 71)Founder, Chairman, CEO & President Comp: $586.04kMr. John F. Glenn (Age 62)CFO & Corporate Secretary Comp: $411.79kMr. Randy WaddellVice President of Worldwide Sales & MarketingMr. Steve KachelmeyerVice President of Regulatory Affairs & Quality AssuranceMr. Lynn NeuhardtVice President of Research & DevelopmentMr. Chris WilliamsonExecutive Vice President of Continuous Improvement & Information TechnologyMr. Matt GarnerControllerMore ExecutivesKey CompetitorsOrthofix MedicalNASDAQ:OFIXEmbectaNASDAQ:EMBCSI-BONENASDAQ:SIBNSurmodicsNASDAQ:SRDXOraSure TechnologiesNASDAQ:OSURView All CompetitorsInsiders & InstitutionsRussell Investments Group Ltd.Sold 44,404 shares on 5/8/2024Ownership: 1.318%Isthmus Partners LLCBought 64,574 shares on 5/8/2024Ownership: 0.568%Swiss National BankBought 1,300 shares on 5/7/2024Ownership: 0.128%LSV Asset ManagementSold 4,800 shares on 5/6/2024Ownership: 0.100%BNP Paribas Financial MarketsBought 9,948 shares on 5/1/2024Ownership: 0.135%View All Insider TransactionsView All Institutional Transactions IRMD Stock Analysis - Frequently Asked Questions Should I buy or sell Iradimed stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRMD shares. View IRMD analyst ratings or view top-rated stocks. What is Iradimed's stock price target for 2024? 3 equities research analysts have issued 12-month price objectives for Iradimed's shares. Their IRMD share price targets range from $60.00 to $65.00. On average, they expect the company's stock price to reach $62.50 in the next twelve months. This suggests a possible upside of 43.9% from the stock's current price. View analysts price targets for IRMD or view top-rated stocks among Wall Street analysts. How have IRMD shares performed in 2024? Iradimed's stock was trading at $47.47 on January 1st, 2024. Since then, IRMD shares have decreased by 8.5% and is now trading at $43.42. View the best growth stocks for 2024 here. When is Iradimed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our IRMD earnings forecast. How were Iradimed's earnings last quarter? Iradimed Corporation (NASDAQ:IRMD) released its quarterly earnings results on Thursday, October, 28th. The medical equipment provider reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.06. The medical equipment provider had revenue of $10.91 million for the quarter, compared to analysts' expectations of $10.39 million. Iradimed had a net margin of 26.48% and a trailing twelve-month return on equity of 24.63%. During the same period last year, the business earned $0.09 earnings per share. How often does Iradimed pay dividends? What is the dividend yield for Iradimed? Iradimed declared a quarterly dividend on Thursday, May 2nd. Investors of record on Monday, May 20th will be paid a dividend of $0.15 per share on Thursday, May 30th. This represents a $0.60 annualized dividend and a yield of 1.38%. The ex-dividend date of this dividend is Friday, May 17th. Read our dividend analysis for IRMD. Is Iradimed a good dividend stock? Iradimed (NASDAQ:IRMD) pays an annual dividend of $0.60 per share and currently has a dividend yield of 1.34%. The dividend payout ratio is 42.55%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, IRMD will have a dividend payout ratio of 34.88% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for IRMD. What ETF holds Iradimed's stock? Ballast Small/Mid Cap ETF holds 30,184 shares of IRMD stock, representing 0.93% of its portfolio. What guidance has Iradimed issued on next quarter's earnings? Iradimed updated its second quarter 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of 0.360-0.390 for the period, compared to the consensus estimate of 0.370. The company issued revenue guidance of $17.6 million-$17.8 million, compared to the consensus revenue estimate of $17.9 million. What other stocks do shareholders of Iradimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR). Who are Iradimed's major shareholders? Iradimed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (1.32%), Isthmus Partners LLC (0.57%), Los Angeles Capital Management LLC (0.39%), Bridge City Capital LLC (0.33%), Conestoga Capital Advisors LLC (0.22%) and Shaker Investments LLC OH (0.16%). Insiders that own company stock include Anthony Vuoto, Christopher K Scott, James B Hawkins, Monty K Allen, Monty K Allen and Roger E Susi. View institutional ownership trends. How do I buy shares of Iradimed? Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IRMD) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm PressObama’s Forever Term [exposed]Porter & CompanyPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society“Crash Insurance” For Your RetirementUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iradimed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
